Literature DB >> 26246144

Loss of Phosphatase and Tensin Homolog in APCs Impedes Th17-Mediated Autoimmune Encephalomyelitis.

Emine Sahin1, Julia S Brunner1, Julia B Kral1, Mario Kuttke1, Leslie Hanzl1, Hannes Datler1, Hannah Paar1, Nick Neuwinger1, Victoria Saferding2, Elisabeth Zinser3, Angela Halfmann4, Klara Soukup4, Eva Hainzl1, Tobias Lohmeyer1, Birgit Niederreiter2, Thomas Haider5, Alexander M Dohnal4, Gerhard Krönke6, Stephan Blüml7, Gernot Schabbauer8.   

Abstract

The PI3K signaling cascade in APCs has been recognized as an essential pathway to initiate, maintain, and resolve immune responses. In this study, we demonstrate that a cell type-specific loss of the PI3K antagonist phosphatase and tensin homolog (PTEN) in myeloid cells renders APCs toward a regulatory phenotype. APCs deficient for PTEN exhibit reduced activation of p38 MAPK and reduced expression of T cell-polarizing cytokines. Furthermore, PTEN deficiency leads to upregulation of markers for alternative activation, such as Arginase 1, with concomitant downregulation of inducible NO synthase in APCs in vitro and in vivo. As a result, T cell polarization was dysfunctional in PTEN(-/-) APCs, in particular affecting the Th17 cell subset. Intriguingly, mice with cell type-specific deletions of PTEN-targeting APCs were protected from experimental autoimmune encephalomyelitis, which was accompanied by a pronounced reduction of IL-17- and IL-22-producing autoreactive T cells and reduced CNS influx of classically activated monocytes/macrophages. These observations support the notion that activation of the PI3K signaling cascade promotes regulatory APC properties and suppresses pathogenic T cell polarization, thereby reducing the clinical symptoms and pathology of experimental autoimmune encephalomyelitis.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26246144     DOI: 10.4049/jimmunol.1402511

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  9 in total

1.  Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity.

Authors:  Yi Huang; Huanyu Wang; Yize Hao; Hualong Lin; Menghao Dong; Jin Ye; Lei Song; Yunzhi Wang; Qingqing Li; Benjie Shan; Yizhou Jiang; Hongqi Li; Zhiming Shao; Guido Kroemer; Huafeng Zhang; Li Bai; Tengchuan Jin; Chao Wang; Yuting Ma; Yongping Cai; Chen Ding; Suling Liu; Yueyin Pan; Wei Jiang; Rongbin Zhou
Journal:  Nat Cell Biol       Date:  2020-05-04       Impact factor: 28.824

Review 2.  PTEN Hamartoma Tumor Syndrome and Immune Dysregulation.

Authors:  Marc Eissing; Lise Ripken; Gerty Schreibelt; Harm Westdorp; Marjolijn Ligtenberg; Romana Netea-Maier; Mihai G Netea; I Jolanda M de Vries; Nicoline Hoogerbrugge
Journal:  Transl Oncol       Date:  2018-11-30       Impact factor: 4.243

3.  PI3K Signaling in Dendritic Cells Aggravates DSS-Induced Colitis.

Authors:  Mario Kuttke; Dominika Hromadová; Ceren Yildirim; Julia S Brunner; Andrea Vogel; Hannah Paar; Sophie Peters; Maria Weber; Melanie Hofmann; Martina Kerndl; Markus Kieler; Hannes Datler; Laszlo Musiejovsky; Manuel Salzmann; Michaela Lang; Klara Soukup; Angela Halfmann; Omar Sharif; Gernot Schabbauer
Journal:  Front Immunol       Date:  2022-04-19       Impact factor: 8.786

4.  The phosphatase PTEN links platelets with immune regulatory functions of mouse T follicular helper cells.

Authors:  Xue Chen; Yanyan Xu; Qidi Chen; Heng Zhang; Yu Zeng; Yan Geng; Lei Shen; Fubin Li; Lei Chen; Guo-Qiang Chen; Chuanxin Huang; Junling Liu
Journal:  Nat Commun       Date:  2022-05-19       Impact factor: 14.919

5.  Comparative Analysis on Abnormal Methylome of Differentially Expressed Genes and Disease Pathways in the Immune Cells of RA and SLE.

Authors:  Qinghua Fang; Tingyue Li; Peiya Chen; Yuzhe Wu; Tingting Wang; Lixia Mo; Jiaxin Ou; Kutty Selva Nandakumar
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

6.  Sustained PI3K Activation exacerbates BLM-induced Lung Fibrosis via activation of pro-inflammatory and pro-fibrotic pathways.

Authors:  Julia Barbara Kral; Mario Kuttke; Waltraud Cornelia Schrottmaier; Birgit Birnecker; Joanna Warszawska; Christina Wernig; Hannah Paar; Manuel Salzmann; Emine Sahin; Julia Stefanie Brunner; Christoph Österreicher; Sylvia Knapp; Alice Assinger; Gernot Schabbauer
Journal:  Sci Rep       Date:  2016-03-14       Impact factor: 4.379

Review 7.  PTEN Inhibition in Human Disease Therapy.

Authors:  Rafael Pulido
Journal:  Molecules       Date:  2018-01-30       Impact factor: 4.411

8.  PTEN drives Th17 cell differentiation by preventing IL-2 production.

Authors:  Hyeong Su Kim; Sung Woong Jang; Wonyong Lee; Kiwan Kim; Hyogon Sohn; Soo Seok Hwang; Gap Ryol Lee
Journal:  J Exp Med       Date:  2017-10-10       Impact factor: 14.307

9.  Myeloid PTEN deficiency impairs tumor-immune surveillance via immune-checkpoint inhibition.

Authors:  M Kuttke; E Sahin; J Pisoni; S Percig; A Vogel; D Kraemmer; L Hanzl; J S Brunner; H Paar; K Soukup; A Halfmann; A M Dohnal; C W Steiner; S Blüml; J Basilio; B Hochreiter; M Salzmann; B Hoesel; G Lametschwandtner; R Eferl; J A Schmid; G Schabbauer
Journal:  Oncoimmunology       Date:  2016-03-28       Impact factor: 7.723

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.